Title: The clinical impact of maternal COVID-19 on mothers, their infants, and placentas with an analysis of vertical transfer of maternal SARS-CoV-2-specific IgG antibodies

Authors: Ward JD^{a,*}, Cornaby C^b, Kato T^c, Gilmore RC^c, Bunch D^d, Miller MB^{a,e}, Boucher RC^c, Schmitz JL^{a,b}, Askin FA^a, and Scanga LR^{a,*}

Affiliations:

^a University of North Carolina School of Medicine, Department of Pathology and Laboratory Medicine, Chapel Hill, North Carolina, USA.

^b Immunology, Histocompatibility and Immunogenetics Laboratories/McLendon Clinical Laboratories UNC Hospitals, Chapel Hill, North Carolina, USA.

^c University of North Carolina School of Medicine, Marisco Lung Institute/UNC Cystic Fibrosis Center, Chapel Hill, North Carolina, USA.

^d University of North Carolina School of Medicine, Department of Medicine, Division of Nephrology and Hypertension, Chapel Hill, North Carolina, USA.

^e Clinical Microbiology and Molecular Microbiology Laboratories, University of North Carolina Health Care, Chapel Hill, North Carolina, USA.

*Corresponding authors:

20 **Jeremy D. Ward** (*Address:* Department of Pathology and Laboratory Medicine, Campus Box #7525,
21 Brinkhous-Bullitt Building, Chapel Hill, NC 27599-7525, United States; *Telephone:* 984-974-1476; *Email:*
22 jeremy.ward@unchealth.unc.edu)

23 **Lori R. Scanga** (*Address:* Department of Surgical Pathology, Women's and Children's Hospitals, 3rd
24 Floor, Room 30149, 101 Manning Drive, Chapel Hill, NC 27514; *Telephone:* 984-974-9142; *Email:*
25 lori.scanga@unchealth.unc.edu)

26

27 ABSTRACT

28 *Introduction:* The effect of SARS-CoV-2 infection on pregnant mothers, the placenta, and infants is not
29 fully understood and sufficiently characterized.

30 *Methods:* We performed a retrospective, observational cohort study in Chapel Hill, NC of 115 mothers
31 with SARS-CoV-2 and singleton pregnancies from December 1, 2019 to May 31, 2021. We performed a
32 chart review to document the infants' weight, length, head circumference, survival, congenital
33 abnormalities, and hearing loss, maternal complications, and placental pathology classified by the
34 Amsterdam criteria.

35 *Results:* The average infant weight, length, and head circumference were all within the normal range
36 for gestational age, the infants had no identifiable congenital abnormalities, and all infants and
37 mothers survived. Only one infant (0.870%) became infected with SARS-CoV-2. Moderate and severe
38 maternal COVID-19 were associated with increased caesarean section, premature delivery, infant NICU
39 admission, and maternal respiratory failure, and were more likely in Type 1 ($p=0.0055$) and Type 2
40 ($p=0.0285$) diabetic mothers. Most placentas ($n=63$, 54.8%) showed normal or non-specific findings,
41 while a subset had mild maternal vascular malperfusion ($n=26$, 22.6%) and/or mild microscopic
42 ascending intrauterine infection ($n=28$, 24.3%).

43 *Discussion:* Most mothers with SARS-CoV-2 and their infants had a routine clinical course. Maternal
44 SARS-CoV-2 infection was not associated with intrauterine fetal demise, infant death, congenital
45 abnormalities, or hearing loss. Infant infection with SARS-CoV-2 was rare and not via the placenta.
46 Most placentas had non-specific findings and a subset showed mild maternal vascular malperfusion
47 and/or mild microscopic ascending intrauterine infection, which were not associated with maternal
48 COVID-19 severity.

49

50 **Keywords:** SARS-CoV-2, Maternal COVID-19, SARS-CoV-2 antibodies, maternal diabetes, maternal

51 vascular malperfusion

52 1. Introduction

53 SARS-CoV-2 is a novel enveloped single positive stranded RNA virus of the coronavirus family [1] that
 54 has infected hundreds of millions of individuals resulting in over 5 million deaths worldwide. This study
 55 was initiated at the beginning of the SARS-CoV-2 pandemic when little was known about the effects in
 56 pregnancy. Therefore, we wanted to determine if SARS-CoV-2 infection causes any specific histologic
 57 change in the placenta, the incidence of SARS-CoV-2 transmission to infants, and the survival outcomes
 58 of the mothers and their infants. Since the initiation of our study, there have been increasing reports
 59 on the effects of SARS-CoV-2 on the placenta. In a recent meta-analysis of these placental studies [2],
 60 no histological findings in the placenta were specific for COVID-19. Moreover, all studies to date have
 61 shown the incidence of trans-placental viral transmission to be very rare and when there is SARS-CoV-2
 62 infection of the placenta, no specific viral changes have been noted [2]. However, a recent small study
 63 [3] demonstrated that placentas positive for SARS-CoV-2 via RNA ISH demonstrated chronic histocytic
 64 intervillitis, perivillous fibrin deposition, and trophoblastic necrosis. Interestingly, 63 percent of the
 65 infants in this study [3] tested negative for SARS-CoV-2, meaning that the placenta may be infected
 66 while the infant is not in a number of cases. Finally, there has been some speculation that moderate
 67 and severe maternal hypoxia may lead to maternal vascular malperfusion (MVM) changes [4].
 68 Therefore, additional studies of SARS-CoV-2 infected mothers are needed to determine the common
 69 and rare effects of SARS-CoV-2 on the placenta.

70

71 To date, many of the studies on SARS-CoV-2 and its effect on the mother, infant, and placenta [4,5]
 72 have been in mothers infected in the third trimester. Due to the length of time for our study we were
 73 able to include a significant proportion of mothers who contracted SARS-CoV-2 in their first or second

74 trimester. Moreover, we were able to follow these infants, in some cases over a year, for congenital
75 birth defects and/or hearing impairment that may be associated with maternal SARS-CoV-2.

76

77 In our study, the incidence of maternal transmission was very low (0.870%) and was not via the
78 placenta. After finding that only one infant in our original cohort became infected with SARS-CoV-2, we
79 conscripted a second small cohort and mothers and their infants to determine if mothers infected with
80 SARS-CoV-2 developed SARS-CoV-2-specific IgG antibodies and if these IgG antibodies were transferred
81 to their newborns. We found that nearly all mothers, except for a single individual mother who was
82 likely immunosuppressed from very recent bacterial sepsis, developed SARS-CoV-2-specific IgG
83 antibodies and transferred all or a majority of these antibodies to their infants. These findings are in
84 keeping with several recent studies [6–8] that demonstrated mothers infected with SARS-CoV-2 do
85 generate SARS-CoV-2-specific IgG antibodies and transfer them to their infants; however, these studies
86 differ on the efficiency of the transfer. Our study adds to these data since we found that at least one of
87 six SARS-CoV-2-specific IgG antibodies we tested were transferred and retained by the infant and that
88 this was irrespective of the trimester of the maternal SARS-CoV-2 infection.

89

90 Overall, our study found most mothers with SARS-CoV-2 infections delivered at term and their infants
91 had medically insignificant to no complications. None of the infants or mothers died during the period
92 of our study, which was over a year for many mother and infant dyads. We also found that no infants
93 had any identifiable birth defects linked to maternal COVID-19 infection. Conversely, 13% of the
94 mothers in our cohort who developed moderate or severe COVID-19, had a statistically significant
95 increase in the incidence of premature births, delivery by C-section, maternal respiratory failure,

maternal supplemental oxygen requirement, delivery complications, preeclampsia and admission of their infants to the NICU. Finally, we found that pre-existing diabetes mellitus was the most significant risk factor for developing moderate or severe maternal COVID-19.

2. Materials and methods

2.1. Study design

This was a retrospective observational consecutive cohort study of mothers with a positive SARS-CoV-2 PCR result during their current pregnancy who delivered at The University of North Carolina (UNC) Hospitals in Chapel Hill, NC, between December 1, 2019 and May 31, 2021, and whose placentas were evaluated by Anatomic Pathology. Their infants were included in the cohort. We excluded mothers and their infants who were not the product of a singleton birth and infants found to have genetic abnormalities. Data was obtained from the electronic medical record (EMR) in accordance with the University of North Carolina at Chapel Hill Internal Review Board-approved study parameters (IRB# 20-2944).

2.2. COVID-19 severity quantification

We utilized a simplification of the WHO ordinal scale [9] to categorize the maternal COVID-19 severity as asymptomatic, mild, moderate, or severe with the numerical score of 1, 2, 3, 4, respectively.

2.3. Newborn weight, length, and head circumference percentiles

116 Newborn weight, length, and head circumference percentiles were based on the WHO 0-2-year-old
117 growth charts [10].

118

119 *2.4. SARS-CoV-2 serologic testing*

120 In a smaller non-consecutive study, from July 10, 2021 to August 31, 2021, we identified 10 mothers
121 who had a positive SARS-CoV-2 PCR during their current pregnancy, had not received a COVID-19
122 vaccination, delivered their infants at UNC Hospital main campus, and both the mother and their infant
123 had enough blood remaining in the laboratory to perform SARS-CoV-2-specific antibody assays. SARS-
124 CoV-2-specific IgG antibodies against the spike tetramer, S1, RBD, S2, and nucleocapsid proteins were
125 detected from patient serum or plasma utilizing the LabScreen COVID plus multiplex bead assay
126 (OneLambda) per manufacturer instructions on the LabScan3D platform (Luminex). These same
127 samples, in addition to appropriate positive and negative controls, were tested for SARS-CoV-2
128 neutralizing antibodies using a surrogate neutralizing antibody assay (GeneScript) per the
129 manufacturer's instructions.

130

131 *2.5. Placenta processing and examination*

132 The placentas were processed and evaluated using standard methods [11]. All noted gross and
133 histologic findings were quantified from the final pathology reports in the EMR. The placentas were
134 assigned to one (or more) of the five Amsterdam consensus group criteria or classified as normal/non-
135 specific if the placental findings did not meet the threshold for one of these classifications [12].

136

137 2.6. Immunohistochemical and RNAScope analysis

138 Immunohistochemistry for SARS coronavirus nucleocapsid (Invitrogen PA1-41098) and RNA in situ
139 hybridization for SARS-CoV-2 RNA (Advanced Cell Diagnostics, 848561) for selected placental tissues
140 were performed as previously described including appropriate positive and negative controls [13,14].

141

142 2.7. Statistical analysis

143 All statistical analyses were performed using GraphPad Prism version 9.2.0 except for polynomial and
144 linear trend analysis, which were performed using Microsoft Excel (Microsoft 365). Chi-square for
145 linear trend, Fischer exact test, Mann-Whitney test, or one-way ANOVA with multiple comparisons
146 between groups using Tukey's test were used as appropriate. Survival curve comparison was
147 performed using the Gehan-Breslow-Wilcoxon test. P values <0.050 were considered significant.

148

149 3. Results

150 3.1. Maternal Characteristics

151 One hundred twenty-five mothers were identified, and 115 mothers, including their placentas and
152 infants, were included in the study (Figure 1). Clinical information that was collected and analyzed is
153 listed in Table 1. The mean (median) maternal age was 29 (28) years with a range of 15 to 42 years old.
154 58% of the mothers were Hispanic, which is substantially increased compared to 9.6%, the estimated
155 Hispanic statewide population of North Carolina [15]. Nine mothers (7.83%) were infected with SARS-
156 CoV-2 in their first trimester, 27 mothers (23.5%) were infected in their second trimester, with the
157 remaining 79 mothers (68.7%) infected in their third trimester. The mean (median) of the first positive
158 test result was 30.5 (34.6) weeks gestation, and ~35% tested positive on admission. The average

159 (median) gestational age at delivery was 38.3 (39 1/7) weeks and 69% were vaginal and 31% were via
160 C-section. 85.2% of mothers were asymptomatic (n=37) or had mild (n=61) symptoms, 13.0% of
161 mothers had moderate (n=9) or severe (n=6) COVID-19, and 1.74% (n=2) mothers did not have their
162 symptoms reported.

163

164 3.2. Severity of Maternal COVID-19 Infection

165 Mothers with severe or moderate COVID-19 were statistically more likely to be Type 1 (p=0.0055) or
166 Type 2 (p=0.0285) diabetics, have respiratory failure (p<0.0001), require supplemental oxygen
167 (p<0.0001), deliver via C-section (p=0.0006), have any delivery complication (p=0.0291), preeclampsia
168 (p=0.0274), or premature infants (p=0.0002) compared to mothers who were mildly ill (less likely) or
169 asymptomatic (least likely). Three of the six severely ill mothers delivered at 26-32 weeks and one
170 severely ill and two of the nine moderately ill mothers delivered at 35-36 weeks due to respiratory
171 failure. 8.70 percent of mothers required supplemental oxygen, which included 44.4% of the
172 moderately and 100% of the severely ill mothers (p<0.0001). Similarly, maternal respiratory failure
173 attributed to COVID-19 was seen in seven mothers (6.09%) and was significantly increased (p<0.0001)
174 in the moderately (11.1%) and severely ill (100%). There was a strong tendency for increased maternal
175 medical complications (p=0.0668) from asymptomatic (least likely) to severely ill (most likely). Mothers
176 with severe COVID-19 delivered prematurely, at an average (median) gestational age of 33.6 (34 1/7)
177 weeks compared to 38.5 (39 0/7) weeks with asymptomatic infection (p<0.0001), 38.7 (39 2/7) weeks
178 with mild COVID-19 (p<0.0001), and 37.5 (37 2/7) weeks with moderate COVID-19 (p=0.0157).
179 Conversely, there was a statistically significant inverse correlation for clinically detected meconium
180 (p=0.0457) in asymptomatic mothers (most likely) versus severely ill (least likely) mothers.

181

182 Subgroup analysis demonstrated a statistically significant difference in delivery complications between
183 mild versus moderate ($p=0.0300$) and mild versus severe ($p=0.0253$) maternal infections. There was a
184 strong tendency for increased delivery complications between asymptomatic versus moderate
185 ($p=0.0691$) and asymptomatic versus severely ill ($p=0.0662$) mothers. There was no statistically
186 significant difference in delivery complications between moderate versus severe maternal infections
187 ($p>0.9999$).

188

189 3.3. Trimester of Maternal COVID-19 Infection

190 There was a statistically significant increase in the maternal requirement for supplemental oxygen
191 ($p=0.0393$), incidence of C-section ($p=0.0012$), presence of clinically noted meconium ($p=0.0241$), and
192 fetal intolerance ($p=0.042$) when progressing from maternal SARS-CoV-2 infection in the first trimester
193 (least risk) to the third trimester (most risk). There was a statistically significant increased odds ratio
194 (OR 3.91, 1.31-11.2, 95% CI) of C-section with a third trimester SARS-CoV-2 infection versus a first
195 trimester ($p=0.0234$) or a second trimester ($p=0.0182$) maternal infection. Conversely, there was a
196 statistically significant increase in group B *Streptococcus* (GBS) infection ($p=0.0240$), preterm labor
197 ($p=0.0101$), and *abruptio placentae* ($p=0.0101$) from first trimester (most risk) to third trimester (least
198 risk) maternal infection.

199

200 3.4. Infant Characteristics

201 In the cohort, there were slightly more male infants than female infants (Figure 2A). Infant
202 birthweights (Figure 2B), newborn lengths (Figure 2C), and head circumferences (Figure 2D) were all
203 within normal parameters for gestational age. There was not a statistically significant difference
204 between the male and female weights ($p=0.2273$) or the male and female infant head circumferences
205 ($p=0.5635$). There was a tendency for the female infants to be shorter than the male infants
206 ($p=0.0680$). On subgroup analysis, there was a statistically significant decrease in the mean infant
207 weights with severe versus mild ($p=0.0246$) or moderate ($p=0.0286$) maternal COVID-19 and a
208 tendency toward lower birth weights ($p=0.0675$) with asymptomatic maternal infections. There was a
209 statistically significant decrease in the mean infant length ($p=0.0372$) with moderate or severe
210 maternal infections. Similarly, there was a statistically significant decrease in infant head
211 circumferences with severe maternal infections versus mild infections ($p=0.0428$).

212

213 Twenty-three (20.0%) of the infants were admitted to the neonatal intensive care unit (NICU) after
214 birth. A severe maternal infection was associated with an increased incidence of admission to the NICU
215 ($p=0.0007$) and premature birth ($p=0.0002$). Subgroup analysis showed significantly increased
216 admission to the NICU after moderate ($p=0.0388$) or severe ($p=0.0042$) versus asymptomatic maternal
217 infections. Similarly, mild versus moderate ($p=0.0035$) and mild versus severe ($p=0.0003$) maternal
218 COVID-19 were associated with an increased risk of NICU admission. Asymptomatic versus severe
219 ($p=0.0007$) and mild versus severe ($p<0.0001$) maternal COVID-19 were associated with a statistically
220 increased risk of premature birth. Finally, all infants were alive at the completion of the study on May
221 31, 2021 and there were no incidents of fetal demise (Supplemental Figure 1).

222

223 Fifteen (13.0%) infants had a reported physical abnormality. The most common (Table 1) was a deep
 224 sacral dimple in three infants (2.61%). However, there were no major or recurring physical
 225 abnormalities seen in any of the infants, including those born after a first trimester maternal SARS-
 226 CoV-2 infection. Five (4.3%) infants failed their newborn hearing screen. Of these 5 infants, 3 passed on
 227 follow up hearing tests, and 2 infants failed again (1.7%). There is insufficient follow up in these two
 228 infants as to the cause of hearing loss and there was no indication that it was secondary to maternal
 229 SARS-CoV-2 infection. All infants were screened for congenital heart disease via pulse oximetry and
 230 100% passed. On follow-up, there were 2 infants that were found to have completely dissimilar
 231 cardiovascular abnormalities.

232

233 3.5. Maternal Transmission

234 Sixty-eight infants (59.1%) were tested for SARS-CoV-2 RNA at 24 hours of life, with many of the infants
 235 (n=40) receiving a second test at 48 hours of life. Of these 68 infants, only one infant (1.47%) was
 236 found to be positive for SARS-CoV-2 by PCR at 24 hours. If we assume that the untested infants were
 237 also negative, the overall incidence of SARS-CoV-2 infection was 0.870% in our cohort. Many of the
 238 infants stayed in the same rooms with their mothers and nearly all the infants were breastfed. There
 239 was no evidence of placental SARS-CoV-2 infection, meaning that transmission of SARS-CoV-2 was
 240 likely not via the placenta (Figure 3 and Supplemental Figure 3). Therefore, we hypothesized that the
 241 lack of SARS-CoV-2 infection in these infants may be due to vertical transfer of SARS-CoV-2-specific IgG
 242 antibodies. In a smaller non-consecutive study, from July 10, 2021 to August 31, 2021, we identified 10
 243 mothers who had a positive SARS-CoV-2 PCR during their current pregnancy, had not received a
 244 COVID-19 vaccination, delivered their infants at UNC Hospital main campus, and both the mother and

245 their infant had enough blood remaining in the laboratory to perform SARS-CoV-2-specific antibody
246 assays. Nine of 10 mothers (90%) had SARS-CoV-2-specific IgG antibodies and these antibodies were
247 detected in the blood of their infants. One mother (10%) did not develop a significant antibody
248 response to SARS-CoV-2, and her infant tested positive for SARS-CoV-2 by PCR. Similar confirmatory
249 results were found with a surrogate assay for SARS-CoV-2 neutralizing antibodies (Figure 4 and
250 Supplemental Table 1).

251

252 *3.6. Placental Pathology*

253 54.8% of the placentas had normal or non-specific findings based on the Amsterdam criteria (Figure
254 5A; see Supplemental Figure 2 for the incidence of specific gross and microscopic findings) [12]. The
255 remaining placentas demonstrated maternal vascular malperfusion (MVM, 22.6%), ascending
256 intrauterine infection (AIUI, 24.3%), villitis of unknown etiology (3.48%), fetal vascular malperfusion
257 (FVM, 0.870%), and/or delayed villous maturation (0.870%). There was no statistically significant
258 difference in any of the Amsterdam criteria or normal/non-specific findings among the severity groups
259 of maternal infection or from first to third trimester COVID-19 infection.

260

261 We performed a subgroup analysis of the placentas with MVM by eliminating confounding causes,
262 including preterm delivery (<37 0/7-weeks), maternal diabetes mellitus, hypertension, and/or pre-
263 eclampsia. The incidence of MVM decreased from 22.6% (n=26) to 13.6% (n=9), which was not
264 statistically significant (p=0.174). We also performed an analogous subgroup analysis of BMI (p=0.563),
265 maternal age (p=0.769), vaginal birth versus C-section (p=0.171), and supplemental oxygen
266 requirement (p=0.382), all of which were not statistically significant. Overall, none of the most

267 common risk factors of MVM significantly explained the increase in MVM, suggesting that SARS-CoV-2
268 may be a contributing factor.

269
270 There was not a statistically significant difference ($p=0.454$) between the male and female placental
271 weights (Figure 5B). The mean (median) placenta weight to birth weight ratio was 7.00 (6.98), 7.03
272 (6.96) for males, and 6.96 (7.04) for females, which was not statistically different ($p=0.948$) (Figure 5C).
273 There was a trend of all the placenta weights toward lower percentiles, with 36.5% (36.9% of the males
274 and 36.7% of the females) being less than the 10th percentile (Figure 5D). The >10th weight percentiles
275 were largely normally distributed overall and in the male infants, while the female infants showed a
276 greater skew of the placental weights to the lower percentiles.

277

278 **4. Discussion**

279 No significant physical or growth abnormalities were identified in any of the infants, including those
280 from first or second trimester maternal COVID-19 infections. There was no fetal demise, and all the
281 infants and mothers were alive at the end of the study. There was no evidence of infant hearing loss or
282 cardiovascular abnormalities conclusively linked to maternal SARS-CoV-2 infection. There was only one
283 incidence of SARS-CoV-2 transmission between a mother and infant (0.870%), for which we found no
284 evidence of placental transmission. In a small sample ($n=10$), the majority (90%) of maternal SARS-CoV-
285 2 infections generated maternal SARS-CoV-2-specific IgG antibodies that were transferred to their
286 infants, likely accounting for the low transmission of SARS-CoV-2 to infants during pregnancy and
287 puerperium. Mothers with moderate or severe maternal infections (13%) were statistically more likely
288 to have preexisting Type 1 or Type 2 diabetes mellitus, and to have multiple and/or more severe

maternal complications including respiratory failure, supplemental oxygen requirement, C-section, and preterm delivery. Twenty percent (23) of the infants in our study were admitted to the NICU, with most of these from mothers with moderate or severe COVID-19.

A strength of our study was its relatively large size and its duration, which allowed us to identify first and second trimester maternal SARS-CoV-2 infections and to follow maternal and infant outcomes. Another feature of the study was that most of the mothers (~90%) in our cohort did not receive specific therapy for SARS-CoV-2, and none of the mothers were vaccinated, allowing our study to characterize the natural course of SARS-CoV-2 on the placenta, mother, and infant. However, a limitation of the study was the lack of truly normal control placentas. The placentas received for pathologic examination at UNC are ordered by clinicians for known or suspected maternal, placental, or fetal conditions and are not sent from uncomplicated deliveries. Our study also lacked blinding to the maternal diagnosis of SARS-CoV-2 infection and allowed access to the mothers' chart, which may present a risk for bias. However, since our results were similar to previously published studies [4][11,16], it is likely that this potential bias did not significantly affect the placental examination.

Recently, it has been shown [17–21] that maternal transmission of SARS-CoV-2 during pregnancy is a rare event, which was confirmed in our current study. A recent review [22] found that breastfeeding, mother-to-infant contact, and the method of delivery did not increase the risk for neonatal SARS-CoV-2 infection. A possible reason for this protection is vertical transfer of SARS-CoV-2-specific antibodies from the mother to the infant. In support of this hypothesis, several recent studies [6–8] have demonstrated the vertical transfer of SARS-CoV-2-specific IgG antibodies. Interestingly, these studies

311 report an efficiency of transfer of these antibodies as low as 25 percent [8] and as high as 87 percent
 312 [6]. However, these studies characterized the vertical transfer of antibodies targeted against a single
 313 SARS-CoV-2 epitope. Conversely, our study simultaneously characterized the transfer of 6 separate
 314 SARS-CoV-2-specific IgG antibodies with different epitopes in mother/infant dyads. While we found
 315 that not every individual antibody successfully transferred from the mother to the infant, when looking
 316 at the transfer at least one antibody from the mother to their infant, the overall efficiency of transfer
 317 was 100 percent. This difference in characterizing six separate SARS-CoV-2-specific antibodies may be
 318 why previous studies [7,8] reported a lower efficiency of placental transfer and why infants remained
 319 protected even when some of the SARS-CoV-2 antibodies were not transferred to them. In support of
 320 this hypothesis, the one mother in our study who did not develop an antibody response at all to SARS-
 321 CoV-2, her infant became infected with SARS-CoV-2. This suggests that the complete absence of
 322 generating maternal SARS-CoV-2-specific IgG antibodies increases the risk of infection of the infant by
 323 the mother. Therefore, testing mothers and/or infants for these SARS-CoV-2 IgG antibodies may be
 324 warranted and considered as a part of the discussion with a mother deciding whether to room in with
 325 their infant while infected with SARS-CoV-2. Nevertheless, additional studies on the transfer and
 326 duration of the protective function of these SARS-CoV-2-specific antibodies are needed.

327

328 Consistent with previous reports [2,4,11], over half of the placentas in our study had no significant
 329 gross or microscopic abnormalities. A minority of the placentas demonstrated MVM (22.6%) and/or
 330 AIUI (24.3%), and these placental findings were typically classified as mild. Notably, the average
 331 placental weight to newborn birth weight ratio was in the normal range, indicating the majority of
 332 placentas did not have significant functional abnormalities. This finding is consistent with most of the

333 infants being of normal weight and size with no definitive abnormalities at birth. However, this study
 334 was conducted before the emergence of the delta and omicron variants in North Carolina. A recent
 335 report [23] and experience from our institution (unpublished data) preliminarily indicates that the
 336 delta variant may be associated with more adverse fetal outcomes and more specific placental
 337 pathology. Therefore, future studies will be needed to determine if there are differences in placental
 338 effects and maternal and fetal outcomes among the SARS-CoV-2 variants.

339
 340 Fortunately, most mothers with SARS-CoV-2 infections acquired during pregnancy delivered at term
 341 and had uncomplicated vaginal deliveries. 31% of the deliveries in our cohort were by C-section, which
 342 is the national average for cesarean delivery in the United States [24]. However, moderate or severe
 343 COVID-19 maternal infection had an incidence of C-section of 55.6% (n=5) and 100% (n=6),
 344 respectively. In addition, pre-existing maternal diabetes mellitus was found to be a significant risk
 345 factor for developing moderate or severe maternal COVID-19 in our cohort, indicating that currently
 346 pregnant women or women wishing to become pregnant with diabetes mellitus should be encouraged
 347 to be vaccinated in order to prevent moderate to severe COVID-19 and its associated complications of
 348 delivery. Finally, we found that a subset of placentas demonstrated MVM with weights below the 10th
 349 percentile, which was not linked to the severity of the maternal COVID-19 infection nor to known risk
 350 factors such as hypertension, preeclampsia, or maternal diabetes. Therefore, future studies will be
 351 needed to determine if there are specific circumstances (e.g., underlying genetic factors, specific
 352 immune responses, particular SARS-CoV-2 variants, etc.), along with the timing of the maternal SARS-
 353 CoV-2 infection that correlates with the development of MVM and significantly decreased placental
 354 weight.

355

356 **Disclosure of interests**

357 The authors declare no conflicts of interest.

358

359 **Contribution to authorship**

360 JDW, FAA, and LRS conceptualized and designed the study. JDW, CC, JLS, TK, RCG, RCB, DB, MBM,
361 collected the data for the study. All authors contributed analysis and interpretation of data and to
362 writing and/or editing of the manuscript and have seen the final version of the manuscript.

363

364 **Financial support**

365 This research did not receive any specific grant from funding agencies in the public, commercial, or
366 not-for-profit sectors.

367

368 **Acknowledgements**

369 SARS-CoV-2 positive tracheal sections from a COVID-19 autopsy were provided by Dr. Alain Borczuk
370 (Weill Cornell Medicine) under IRB-approved protocols # 20-04021880 and 20-04021796. We thank
371 Shelby Currier, Nicky Gerken, Steve Holmes, April Kemper, and Andre Phelan who are pathology
372 assistants at UNC for their gross dissection and histologic sampling of many of the placentas in this
373 study. We thank the Obstetric, Family Medicine, and Pediatric nurses, residents and faculty for their
374 hard work caring for the mothers and their infants in this study. Finally, we thank the mothers and
375 infants involved in this study.

References

- [1] P. V'kovski, A. Kratzel, S. Steiner, H. Stalder, V. Thiel, Coronavirus biology and replication: implications for SARS-CoV-2, *Nat. Rev. Microbiol.* 19 (2021) 155–170. <https://doi.org/10.1038/s41579-020-00468-6>.
- [2] J.-T. Suhren, A. Meinardus, K. Hussein, N. Schaumann, Meta-analysis on COVID-19-pregnancy-related placental pathologies shows no specific pattern, *Placenta*. 117 (2022) 72–77. <https://doi.org/10.1016/j.placenta.2021.10.010>.
- [3] J.C. Watkins, V.F. Torous, D.J. Roberts, Defining Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Placentitis, *Arch. Pathol. Lab. Med.* 145 (2021) 1341–1349. <https://doi.org/10.5858/arpa.2021-0246-SA>.
- [4] M.C. Sharps, D.J.L. Hayes, S. Lee, Z. Zou, C.A. Brady, Y. Almoghrabi, A. Kerby, K.K. Tamber, C.J. Jones, K.M. Adams Waldorf, A.E.P. Heazell, A structured review of placental morphology and histopathological lesions associated with SARS-CoV-2 infection, *Placenta*. 101 (2020) 13–29. <https://doi.org/10.1016/j.placenta.2020.08.018>.
- [5] M. Mirbeyk, A. Saghaazadeh, N. Rezaei, A systematic review of pregnant women with COVID-19 and their neonates, *Arch. Gynecol. Obstet.* 304 (2021) 5–38. <https://doi.org/10.1007/s00404-021-06049-z>.
- [6] D.D. Flannery, S. Gouma, M.B. Dhudasia, S. Mukhopadhyay, M.R. Pfeifer, E.C. Woodford, J.E. Triebwasser, J.S. Gerber, J.S. Morris, M.E. Weirick, C.M. McAllister, M.J. Bolton, C.P. Arevalo, E.M. Anderson, E.C. Goodwin, S.E. Hensley, K.M. Puopolo, Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios, *JAMA Pediatr.* 175 (2021) 594–600. <https://doi.org/10.1001/jamapediatrics.2021.0038>.
- [7] A.G. Edlow, J.Z. Li, A.-R.Y. Collier, C. Atyeo, K.E. James, A.A. Boatín, K.J. Gray, E.A. Bordt, L.L. Shook, L.M. Yonker, A. Fasano, K. Diouf, N. Croul, S. Devane, L.J. Yockey, R. Lima, J. Shui, J.D. Matute, P.H. Lerou, B.O. Akinwunmi, A. Schmidt, J. Feldman, B.M. Hauser, T.M. Caradonna, D. De la Flor, P. D'Avino, J. Regan, H. Corry, K. Coxen, J. Fajnzylber, D. Pepin, M.S. Seaman, D.H. Barouch, B.D. Walker, X.G. Yu, A.J. Kaimal, D.J. Roberts, G. Alter, Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic, *JAMA Netw. Open.* 3 (2020) e2030455. <https://doi.org/10.1001/jamanetworkopen.2020.30455>.
- [8] N.T. Joseph, C.M. Dude, H.P. Verkerke, L.S. Irby, A.L. Dunlop, R.M. Patel, K.A. Easley, A.K. Smith, S.R. Stowell, D.J. Jamieson, V. Velu, M.L. Badell, Maternal Antibody Response, Neutralizing Potency, and Placental Antibody Transfer After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, *Obstet. Gynecol.* 138 (2021) 189–197. <https://doi.org/10.1097/AOG.0000000000004440>.
- [9] J.C. Marshall, S. Murthy, J. Diaz, N. Adhikari, D.C. Angus, Y.M. Arabi, K. Baillie, M. Bauer, S. Berry, B. Blackwood, M. Bonten, F. Bozza, F. Brunkhorst, A. Cheng, M. Clarke, V.Q. Dat, M. de Jong, J. Denholm, L. Derde, J. Dunning, X. Feng, T. Fletcher, N. Foster, R. Fowler, N. Gobat, C. Gomersall, A. Gordon, T. Glueck, M. Harhay, C. Hodgson, P. Horby, Y.J. Kim, R. Kojan, B. Kumar, J. Laffey, D. Malvey, I. Martin-Loeches, C. McArthur, D. McAuley, S. McBride, S. McGuinness, L. Merson, S. Morpeth, D. Needham, M. Netea, M.D. Oh, S. Phyu, S. Piva, R. Qiu, H. Salisu-Kabara, L. Shi, N. Shimizu, J. Sinclair, S. Tong, A. Turgeon, T. Uyeki, F. van de Veerdonk, S. Webb, P. Williamson, T.

- 418 Wolf, J. Zhang, A minimal common outcome measure set for COVID-19 clinical research, *Lancet*
419 *Infect. Dis.* 20 (2020) e192–e197. [https://doi.org/10.1016/S1473-3099\(20\)30483-7](https://doi.org/10.1016/S1473-3099(20)30483-7).
- 420 [10] World Health Organization, Child growth standards, (n.d.). [https://www.who.int/toolkits/child-](https://www.who.int/toolkits/child-growth-standards/standards)
421 [growth-standards/standards](https://www.who.int/toolkits/child-growth-standards/standards) (accessed September 11, 2021).
- 422 [11] D. Levitan, V. London, R.A. McLaren, J.D. Mann, K. Cheng, M. Silver, K.S. Balhotra, S. McCalla, K.
423 Loukeris, Histologic and Immunohistochemical Evaluation of 65 Placentas from Women with
424 Polymerase Chain Reaction–Proven Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
425 2) Infection, *Arch. Pathol. Lab. Med.* 145 (2021) 648–656. [https://doi.org/10.5858/arpa.2020-](https://doi.org/10.5858/arpa.2020-0793-SA)
426 [0793-SA](https://doi.org/10.5858/arpa.2020-0793-SA).
- 427 [12] T.Y. Khong, E.E. Mooney, I. Ariel, N.C.M. Balmus, T.K. Boyd, M.A. Brundler, H. Derricott, M.J.
428 Evans, O.M. Faye-Petersen, J.E. Gillan, A.E.P. Heazell, D.S. Heller, S.M. Jacques, S. Keating, P.
429 Kelehan, A. Maes, E.M. McKay, T.K. Morgan, P.G.J. Nikkels, W.T. Parks, R.W. Redline, I.
430 Scheimberg, M.H. Schoots, N.J. Sebire, A. Timmer, G. Turowski, J.P. Van Der Voorn, I. Van
431 Lijnschoten, S.J. Gordijn, Sampling and definitions of placental lesions Amsterdam placental
432 workshop group consensus statement, in: *Arch. Pathol. Lab. Med.*, Arch Pathol Lab Med, 2016:
433 pp. 698–713. <https://doi.org/10.5858/arpa.2015-0225-CC>.
- 434 [13] Y.J. Hou, K. Okuda, C.E. Edwards, D.R. Martinez, T. Asakura, K.H. Dinno, T. Kato, R.E. Lee, B.L.
435 Yount, T.M. Mascenik, G. Chen, K.N. Olivier, A. Ghio, L.V. Tse, S.R. Leist, L.E. Gralinski, A. Schäfer,
436 H. Dang, R. Gilmore, S. Nakano, L. Sun, M.L. Fulcher, A. Livraghi-Butrico, N.I. Nicely, M. Cameron,
437 C. Cameron, D.J. Kelvin, A. de Silva, D.M. Margolis, A. Markmann, L. Bartelt, R. Zumwalt, F.J.
438 Martinez, S.P. Salvatore, A. Borczuk, P.R. Tata, V. Sontake, A. Kimple, I. Jaspers, W.K. O’Neal, S.H.
439 Randell, R.C. Boucher, R.S. Baric, SARS-CoV-2 Reverse Genetics Reveals a Variable Infection
440 Gradient in the Respiratory Tract, *Cell*. 182 (2020) 429-446.e14.
441 <https://doi.org/10.1016/J.CELL.2020.05.042>.
- 442 [14] N. Huang, P. Pérez, T. Kato, Y. Mikami, K. Okuda, R.C. Gilmore, C.D. Conde, B. Gasmi, S. Stein, M.
443 Beach, E. Pelayo, J.O. Maldonado, B.A. Lafont, S.I. Jang, N. Nasir, R.J. Padilla, V.A. Murrah, R.
444 Maile, W. Lovell, S.M. Wallet, N.M. Bowman, S.L. Meinig, M.C. Wolfgang, S.N. Choudhury, M.
445 Novotny, B.D. Aevermann, R.H. Scheuermann, G. Cannon, C.W. Anderson, R.E. Lee, J.T.
446 Marchesan, M. Bush, M. Freire, A.J. Kimple, D.L. Herr, J. Rabin, A. Grazioli, S. Das, B.N. French, T.
447 Pranzatelli, J.A. Chiorini, D.E. Kleiner, S. Pittaluga, S.M. Hewitt, P.D. Burbelo, D. Chertow, D.E.
448 Kleiner, M.S. De Melo, E. Dikoglu, S. Desai, K. Ylaya, J.Y. Chung, G. Smith, D.S. Chertow, K.M.
449 Vannella, M. Ramos-Benitez, S.C. Ramelli, S.J. Samet, A.L. Babyak, L.P. Valenica, M.E. Richert, N.
450 Hays, M. Purcell, S. Singireddy, J. Wu, J. Chung, A. Borth, K. Bowers, A. Weichold, D. Tran, R.J.
451 Madathil, E.M. Krause, D.L. Herr, J. Rabin, J.A. Herrold, A. Tabatabai, E. Hochberg, C. Cornachione,
452 A.R. Levine, M.T. McCurdy, K.K. Saharia, Z. Chancer, M.A. Mazzeffi, J.E. Richards, J.W. Eagan, Y.
453 Sangwan, I. Sequeira, S. A. Teichmann, A. J. Kimple, K. Frank, J. Lee, R.C. Boucher, S.A. Teichmann,
454 B.M. Warner, K.M. Byrd, SARS-CoV-2 infection of the oral cavity and saliva, *Nat. Med.* 27 (2021)
455 892–903. <https://doi.org/10.1038/S41591-021-01296-8>.
- 456 [15] North Carolina’s Hispanic Community: 2019 Snapshot | Carolina Demography, (n.d.).
457 [https://www.ncdemography.org/2019/09/26/north-carolinas-hispanic-community-2019-](https://www.ncdemography.org/2019/09/26/north-carolinas-hispanic-community-2019-snapshot/)
458 [snapshot/](https://www.ncdemography.org/2019/09/26/north-carolinas-hispanic-community-2019-snapshot/) (accessed September 11, 2021).
- 459 [16] P.Z. Rebutini, A.C. Zanchettin, E.T.S. Stonoga, D.M.M. Prá, A.L.P. de Oliveira, F. da S. Dezidério,
460 A.S. Fonseca, J.C.H. Dagostini, E.C. Hlatchuk, I.N. Furuie, J. da S. Longo, B.M. Cavalli, C.L.T. Dino,
461 V.M. de C.H. Dias, A.P. Percicote, M.B. Nogueira, S.M. Raboni, N.S. de Carvalho, C. Machado-
462 Souza, L. de Noronha, Association Between COVID-19 Pregnant Women Symptoms Severity and

Placental Morphologic Features, *Front. Immunol.* 12 (2021).

<https://doi.org/10.3389/fimmu.2021.685919>.

- [17] D.A. Schwartz, An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: Maternal coronavirus infections and pregnancy outcomes, *Arch. Pathol. Lab. Med.* 144 (2020) 799–805. <https://doi.org/10.5858/arpa.2020-0901-SA>.
- [18] F. Parazzini, R. Bortolus, P.A. Mauri, A. Favilli, S. Gerli, E. Ferrazzi, Delivery in pregnant women infected with SARS-CoV-2: A fast review, *Int. J. Gynecol. Obstet.* 150 (2020) 41–46. <https://doi.org/10.1002/ijgo.13166>.
- [19] B.J.F. Huntley, E.S. Huntley, D. Di Mascio, T. Chen, V. Berghella, S.P. Chauhan, Rates of maternal and perinatal mortality and vertical transmission in pregnancies complicated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A systematic review, *Obstet. Gynecol.* 136 (2020) 303–312. <https://doi.org/10.1097/AOG.0000000000004010>.
- [20] J. Juan, M.M. Gil, Z. Rong, Y. Zhang, H. Yang, L.C. Poon, Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic review, *Ultrasound Obstet. Gynecol.* 56 (2020) 15–27. <https://doi.org/10.1002/uog.22088>.
- [21] D. Di Mascio, A. Khalil, G. Saccone, G. Rizzo, D. Buca, M. Liberati, J. Vecchiet, L. Nappi, G. Scambia, V. Berghella, F. D'Antonio, Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis, *Am. J. Obstet. Gynecol. MFM.* 2 (2020) 100107. <https://doi.org/10.1016/j.ajogmf.2020.100107>.
- [22] K.F. Walker, K. O'Donoghue, N. Grace, J. Dorling, J.L. Comeau, W. Li, J.G. Thornton, Maternal transmission of SARS-COV-2 to the neonate, and possible routes for such transmission: a systematic review and critical analysis, *BJOG Int. J. Obstet. Gynaecol.* 127 (2020) 1324–1336. <https://doi.org/10.1111/1471-0528.16362>.
- [23] M. Guan, E. Johannesen, C.Y. Tang, A.L. Hsu, C.L. Barnes, M. Burnam, J.A. McElroy, X.-F. Wan, Intrauterine fetal demise in the third trimester of pregnancy associated with mild infection with the SARS-CoV-2 Delta variant without protection from vaccination, *J. Infect. Dis.* (2022) jiac007. <https://doi.org/10.1093/infdis/jiac007>.
- [24] Stats of the States - Cesarean Delivery Rates, (n.d.). https://www.cdc.gov/nchs/pressroom/sosmap/cesarean_births/cesareans.htm (accessed September 11, 2021).
- [25] T. Boyd, D. Gang, G. Lis, A. Juozokas, S. Pflueger, Normative values for placental weights (N= 15,463), *Mod Pathol.* 12 (1999).

497 **Table 1:**

	Entire Cohort (n=115)	Asymptomatic COVID19 (n=37)	Mild COVID19 (n=61)	Moderate COVID19 (n=9)	Severe COVID19 (n=6)	First Trimester COVID19 (n=9)	Second Trimester COVID19 (n=27)	Third Trimester COVID19 (n=79)
Average (median) maternal age	29 (28)	30 (30)	28 (27)	28 (26)	32 (31)	27 (27)	28 (28)	29 (28)
Race/Ethnicity								
Latina/Hispanic	58.3% [67]	62.2% [23]	59.0% [36]	44.4% [4]	50.0% [3]	88.9% [8]	55.6% [15]	55.7% [44]
African American/African	17.4% [20]	13.5% [5]	23.0% [14]	11.1% [1]	0% [0]	0% [0]	22.2% [6]	17.7% [14]
White, Non-Hispanic	17.4% [20]	18.9% [7]	13.1% [8]	22.2% [2]	33.3% [2]	11.1% [1]	18.5% [5]	17.7% [14]
East Asian	1.74% [2]	0% [0]	1.64% [1]	0% [0]	16.7% [1]	0% [0]	0% [0]	2.50% [2]
Mixed heritage	2.61% [3]	2.70% [1]	3.28% [2]	0% [0]	0% [0]	0% [0]	3.70% [1]	2.50% [2]
No race/ethnicity available	2.61% [3]	2.70% [1]	0% [0]	22.2% [2]	0% [0]	0% [0]	0% [0]	4.00% [3]
Average (median) maternal BMI	30.30 (28.57)	29.83 (27.96)	30.59 (29.67)	33.04 (33.00)	28.97 (29.00)	28.73 (26.96)	31.79 (31.00)	29.93 (28.25)
Average (median) gestational age at first SARS-CoV-2-positive test	30.5 (34 4/7) weeks	35.9 (38 6/7) weeks	26.76 (30 2/7) weeks	32.9 (34 4/7) weeks	31.97 (31.93) weeks	7.63 (8 6/7) weeks	20.39 (20 4/7) weeks	36.63 (37 4/7) weeks
Infection in first trimester	7.83% [9]	2.70% [1]	13.1% [8]	0% [0]	0% [0]	–	–	–
Infection in second trimester	23.5% [27]	8.11% [3]	36.1% [22]	11.1% [1]	0% [0]	–	–	–
Infection in third trimester	68.7% [79]	89.2% [33]	50.8% [31]	88.9% [8]	100% [6]	–	–	–
Infection <=34 0/7 weeks of third trimester	16.5% [19]	5.41% [2]	14.8% [9]	11.1% [1]	83.3% [5]	–	–	–
Infection >=34 1/7 weeks of third trimester	52.2% [60]	83.8% [31]	36.1% [22]	33.3% [3]	16.7% [1]	–	–	–
First Pregnancy	26.1% [30]	18.9% [7]	27.9% [17]	44.4% [4]	16.7% [1]	44.4% [4]	18.5% [5]	26.6% [21]
Average (median) SARS-CoV-2 Ct Value	26.6 (25.7)	33.7 (38.3) ^{a,b,c}	20.2 (19.5) ^{a,b}	21.6 (21.4) ^a	18.2 (17.2) ^{a,c}	21.0 (22.2) ^q	20.8 (20.7) ^q	28.7 (30.6) ^q
Average (median) gestational age at delivery	38.3 (39 1/7) weeks	38.5 (39 0/7) weeks ^{d,e}	38.7 (39 2/7) weeks ^{d,f}	37.5 (37 2/7) weeks ^{d,g}	33.6 (34 1/7) weeks ^{d,e,f,g}	37.5 (38 5/7) weeks	38.68 (39 3/7) weeks	38.23 (39 0/7) weeks
Required treatment with oxygen	8.70% [10]	0% [0] ^{ii, jj, kk}	0% [0] ^{ii, ll, mm}	44.4% [4] ^{ii, jj, ll, nn}	100% [6] ^{mm, nn}	0% [0] ^r	0% [0] ^r	2.7% [10] ^r
Type of Delivery								
Vaginal	68.7% [79]	75.7% [28] ^{oo, pp}	73.8% [45] ^{oo, qq}	44.4% [4] ^{oo}	0% [0] ^{oo, pp, qq}	100% [9] ^{s,t}	85.2% [23] ^{s,u}	59.5% [47] ^{s, tu}
Cesarean Section	31.3% [36]	24.3% [9] ^{oo, pp}	26.2% [16] ^{oo, qq}	55.6% [5] ^{oo}	100% [6] ^{oo, pp, qq}	0% [0] ^{s,t}	14.8% [4] ^{s,u}	40.5% [32] ^{s, tu}
Pregnancy-related pre-existing medical comorbidities								
Hypertension	22.6%	16.2% [6]	26.2% [16]	33.3% [3]	16.7% [1]	11.1% [1]	22.2% [6]	24.1% [19]

	[26]							
Chronic	8.70% [10]	8.11% [3]	8.20% [5]	11.1% [1]	16.7% [1]	11.1% [1]	11.1% [3]	7.59% [6]
Gestational	13.9% [16]	8.11% [3]	18.0% [11]	22.2% [2]	0% [0]	0% [0]	11.1% [3]	16.5% [13]
Diabetes mellitus	14.8% [17]	13.5% [5]	11.5% [7]	33.3% [3]	33.3% [2]	11.1% [1]	7.41% [2]	17.7% [14]
Gestational	9.57% [11]	10.8% [4]	9.84% [6]	11.1% [1]	0% [0]	11.1% [1]	3.70% [1]	11.4% [9]
T1DM	0.87% [1]	0% [0] ^{ddd}	0% [0] ^{ddd}	0% [0] ^{ddd}	16.7% [1] ^{ddd}	0% [0]	0% [0]	1.27% [1]
T2DM	4.35% [5]	2.70% [1] ^{eee}	1.64% [1] ^{eee, fff}	22.2% [2] ^{eee, fff}	16.7% [1] ^{eee}	0% [0]	3.70% [1]	5.06% [4]
Current smoker during pregnancy	6.96% [8]	8.11% [3]	6.56% [4]	11.1% [1]	0% [0]	0% [0]	3.70% [1]	8.86% [7]
Any birth complication reported by clinical team	55.7% [64]	54.1% [20] ^{rr}	47.5% [29] ^{rr, ss, tt}	88.9% [8] ^{rr, ss}	100% [6] ^{rr, tt}	44.4% [4]	44.4% [12]	60.8% [48]
Meconium	13.9% [16]	24.3% [9] ^{uu}	9.84% [6] ^{uu}	11.1% [1] ^{uu}	0% [0] ^{uu}	0% [0] ^v	3.70% [1] ^v	17.7% [14] ^v
Chorioamnionitis	6.09% [7]	5.41% [2]	6.56% [4]	11.1% [1]	0% [0]	0% [0]	7.41% [2]	6.33% [5]
pPROM/PROM	2.61% [3]	5.41% [2]	1.64% [1]	0% [0]	0% [0]	0% [0]	0% [0]	3.80% [3]
Intrauterine growth restriction	3.48% [4]	8.11% [3]	1.64% [1]	0% [0]	0% [0]	0% [0]	0% [0]	5.06% [4]
Nuchal chord	11.3% [13]	16.2% [6]	11.5% [7]	0% [0]	0% [0]	0% [0]	11.1% [3]	12.7% [10]
Hemorrhage	12.2% [14]	13.5% [5]	11.5% [7]	11.1% [1]	16.7% [1]	11.1% [1]	14.8% [4]	11.4% [9]
Fetal intolerance	12.2% [14]	13.5% [5]	9.84% [6]	22.2% [2]	16.7% [1]	0% [0] ^w	3.70% [1] ^w	16.5% [13] ^w
Failure to progress	7.83% [9]	5.41% [2]	9.84% [6]	11.1% [1]	0% [0]	0% [0]	7.40% [2]	8.86% [7]
Preeclampsia/HELLP syndrome	13.0% [15]	5.41% [2] ^{uu, vv}	11.5% [7] ^{uu, ww}	44.4% [4] ^{uu, vv, ww}	16.7% [1] ^{uu}	11.1% [1]	0% [0]	11.4% [9]
Elevated BP	0.87% [1]	2.70% [1]	0% [0]	0% [0]	0% [0]	0% [0]	0% [0]	1.27% [1]
Fever	2.61% [3]	0% [0]	3.28% [2]	11.1% [1]	0% [0]	0% [0]	0% [0]	3.80% [3]
Maternal respiratory failure	6.09% [7]	0% [0] ^{xx, yy}	0% [0] ^{xx, zz}	11.1% [1] ^{xx, aaa}	100% [6] ^{xx, yy, zz, aaa}	0% [0]	0% [0]	8.86% [7]
Medical maternal complications	2.61% [3]	0% [0] ^{bbb}	1.64% [1] ^{ccc}	22.2% [2] ^{bbb, ccc}	0% [0]	11.1% [1]	0% [0]	2.53% [2]
Severe intrahepatic cholestasis of pregnancy	0.87% [1]	–	1.64% [1]	–	–	11.1% [1]	–	–
DKA/starvation ketosis in the setting of T2DM and symptomatic COVID	0.87% [1]	–	–	11.1% [1]	–	–	–	1.27% [1]
Cholestasis of pregnancy	0.87% [1]	–	–	11.1% [1]	–	–	–	1.27% [1]
GBS positive	6.96% [8]	2.70% [1]	6.56% [4]	11.1% [1]	16.7% [1]	33.3% [3] ^{x,y,z}	3.71% [1] ^{x,y}	5.06% [4] ^{x,z}
Preterm labor	0.87% [1]	0% [0]	1.64% [1]	0% [0]	0% [0]	11.1% [1] ^{aa}	0% [0] ^{aa}	0% [0] ^{aa}
Abruptio placenta	0.87% [1]	0% [0]	1.64% [1]	0% [0]	0% [0]	11.1% [1] ^{bb}	0% [0] ^{bb}	0% [0] ^{bb}
Retained placenta	0.87% [1]	0% [0]	1.64% [1]	0% [0]	0% [0]	0% [0]	3.71% [1]	0% [0]

Oligohydramnios	0.87% [1]	2.70% [1]	0% [0]	0% [0]	0% [0]	0% [0]	0% [0]	1.27% [1]
Shoulder dystocia	0.87% [1]	0% [0]	1.64% [1]	0% [0]	0% [0]	0% [0]	3.71% [1]	0% [0]
Medications		0% [0]	0% [0]	66.7% [6]	83.3% [5]			
Corticosteroids	6.09% [7]			44.4% [4]	50.0% [3]			
Remdesivir	4.35% [5]	–	–	55.5% [5]	83.3% [5]			
Bamlanivimab	1.74% [2]	–	–	11.1% [1]	16.7% [1]			
Enoxaparin	1.74% [2]	–	–	11.1% [1]	16.7% [1]			
COVID-19 Convalescent Plasma	0.87% [1]	–	–	–	16.7% [1]			
Average (median) newborn weight	3142 (3235) g	3099 (3250) g	3210 (3245) g	3380 (3135) g	2394 (2590) g	3050 (3240) g	3383 (3325) g	3140 (3175) g
Average (median) newborn length	49.1 (50.8) cm	48.7 (49.5) g	49.6 (50.8) cm	51.0 (51.8) cm	45.0 (45.1) cm	49.8 (50.8) cm	50.2 (50.8) cm	48.7 (50.0) cm
Average (median) newborn head circumference	34.0 (34.3) cm	33.5 (34.3) g	34.5 (34.3) cm	34.9 (34.9) cm	30.9 (32.0) cm	33.4 (34.3) cm	34.2 (34.5) cm	34.0 (34.3) cm
Average (median) APGAR scores								
1 minute	7.5 (8.0)	7.5 (8.0)	7.9 (8.0)	5.9 (6.5)	6.3 (7.0)	8.0 (8.0)	7.7 (8.0)	7.4 (8.0)
5 minutes	8.6 (9.0)	8.8 (9.0)	8.7 (9.0)	8.0 (8.5)	8.0 (9.0)	8.8 (9.0)	8.7 (9.0)	8.6 (9.0)
Failed first hearing screen	4.35% [5]	5.41% [2]	3.28% [2]	11.1% [1]	0% [0]	0% [0]	3.70% [1]	5.1% [4]
Failed follow-up hearing testing	1.74% [2]	0% [0]	1.64% [1]	11.1% [1]	–	–	3.70% [1]	1.27% [1]
Passed congenital heart screen	100% [115]	100% [37]	100% [61]	100% [9]	100% [6]	100% [9]	100% [27]	100% [79]
NICU/PICU admission	20.0% [23]	18.9% [7] ^{h,i,j}	9.84% [6] ^{h,k,l}	55.6% [5] ^{h,i,k}	83.3% [5] ^{h,j,l}	11.1% [1]	7.41% [2]	25.3% [20]
Newborns tested for SARS-CoV-2	59.1% [68]	89.2% [33]	39.3% [24]	66.7% [6]	83.3% [5]	0% [0] ^{cc}	22.2% [6] ^{cc, dd}	78.5% [62] ^{cc, dd}
Positive	1.47% [1]	3.03% [1]	0% [0]	0% [0]	0% [0]	–	0% [0]	1.61% [1]
Negative	98.5% [67]	97.0% [32]	100% [24]	100% [6]	100% [5]	–	100% [6]	98.4% [61]
Newborns with any physical abnormality	13.0% [15]	13.5% [5]	11.5% [7]	22.2% [2]	16.7% [1]	0% [0]	18.5% [5]	12.7% [10]
Sacral dimple	2.61% [3]	2.70% [1]	1.64% [1]	0% [0]	16.7% [1]	–	3.70% [1]	2.53% [2]
Cardiovascular abnormality	1.74% [2]	–	3.28% [2]	–	–	–	3.70% [1]	1.27% [1]
Spina bifida occulta with sacral hair tuft	0.87% [1]	–	1.64% [1]	–	–	–	3.70% [1]	–
Bilateral hydroceles	0.87% [1]	–	1.64% [1]	–	–	–	3.70% [1]	–
Transverse palmar crease and widened toe gap	0.87% [1]	–	1.64% [1]	–	–	–	3.70% [1]	–
Congenital phalangeal synostosis bilateral 4 th and 5 th PIP joints of the hand	0.87% [1]	–	–	11.1% [1]	–	–	–	1.61% [1]
Mild micrognathia	0.87% [1]	–	–	11.1% [1]	–	–	–	1.61% [1]
Right ear tag, caput molding, and diastasis recti	0.87% [1]	–	1.64% [1]	–	–	–	–	1.61% [1]

Mild deviation of the penile raphe	0.87% [1]	—	1.64% [1]	—	—	—	3.70% [1]	—
Low set ears and prominent epicanthal fold concerning for Trisomy 21 (with normal karyotype)	0.87% [1]	2.70% [1]	—	—	—	—	—	1.61% [1]
Scaphocephalic head	0.87% [1]	2.70% [1]	—	—	—	—	—	1.61% [1]
Premature (<37 weeks)	12.2% [14]	10.8% [4] ^{mn}	4.92% [3] ^{mo}	22.2% [2] ^{mp}	83.5% [5] ^{mn,o,p}	11.1% [1]	7.41% [2]	13.9% [11]
Large for gestational age	6.96% [8]	5.41% [2]	6.56% [4]	22.2% [2]	0% [0]	0% [0]	7.41 [2]	7.59% [6]
Small for gestational age	3.48% [4]	8.11% [3]	1.64% [1]	0% [0]	0% [0]	0% [0]	0% [0]	5.06% [4]
Average (median) placenta weight	459 (450) g	445 (440) g	467 (450) g	502 (495) g	389 (373) g	453 (425) g	458 (450) g	460 (450) g
Average (median) fetal weight to placenta weight ratio	7.00 (6.98)	7.13 (6.86)	7.01 (7.12)	6.93 (7.04)	6.39 (6.41)	6.77 (6.71)	7.30 (7.26)	6.92 (6.89)
Amsterdam Criteria Classification ^{ec,ff}								
Maternal vascular malperfusion	22.6% [26]	27.0% [10]	18.0% [11] ^{gg}	22.2% [2]	33.3% [2] ^{gg}	0% [0] ^{hh}	22.2% [6]	25.3% [20] ^{hh}
Fetal vascular malperfusion ^{†††}	0.87% [1]	0% [0]	1.64% [1] ^{gg}	0% [0]	0% [0] ^{gg}	0% [0] ^{hh}	0% [0]	1.27% [1] ^{hh}
Delayed villous maturation ^{†††}	0.87% [1]	2.70% [1]	0% [0] ^{gg}	0% [0]	0% [0] ^{gg}	0% [0] ^{hh}	0% [0]	1.27% [1] ^{hh}
Ascending intrauterine infection	24.3% [28]	13.5% [5]	31.1% [19] ^{gg}	33.3% [3]	0% [0] ^{gg}	44.4% [4] ^{hh}	14.8% [4]	25.3% [20] ^{hh}
Villitis of unknown etiology	3.48% [4]	2.70% [1]	3.28% [2] ^{gg}	11.1% [1]	0% [0] ^{gg}	0% [0] ^{hh}	0% [0]	5.06% [4] ^{hh}
Normal or some non-specific findings	54.8% [63]	56.8% [21]	54.1% [33] ^{gg}	44.4% [4]	66.7% [4] ^{gg}	55.6% [5] ^{hh}	70.4% [19]	49.4% [39] ^{hh}

498

499 ^a p < 0.0001 with one-way ANOVA, ^b p < 0.0001 with Tukey's multiple comparisons test, ^c p = 0.0339 with Tukey's
500 multiple comparisons test, ^d p < 0.0001 with one-way ANOVA, ^e p < 0.0001 with Tukey's multiple comparisons
501 test, ^f p < 0.0001 with Tukey's multiple comparisons test, ^g p = 0.0157 with Tukey's multiple comparisons test, ^h p
502 = 0.0007 with Chi-square test for trend, ⁱ p = 0.0388 with Fisher's exact test, ^j p = 0.0042 with Fisher's exact test,
503 ^k p = 0.0035 with Fisher's exact test, ^l p = 0.0003 with Fisher's exact test, ^m p = 0.0002 with Chi-square test for
504 trend, ⁿ p = 0.0007 with Fisher's exact test, ^o p < 0.0001 with Fisher's exact test, ^p p = 0.0406 with Fisher's exact
505 test; ^q p = 0.0341 with one-way ANOVA, with no statistical significance between the trimesters with Tukey's
506 multiple comparison test (p=0.0717 between second and third trimesters), ^r p = 0.0393 with Chi-square test for
507 trend with no statistical significance between the trimesters with Fisher's exact test (p = 0.0616 between the
508 second and third trimesters), ^s p = 0.0012 with Chi-square test for trend, ^t p = 0.0234 with Fisher exact test, ^u p =
509 0.0182 with Fisher exact test (2nd to 3rd trimester comparison), ^v p = 0.0241 with Chi-square test for trend, ^w p =
510 0.0421 with Chi-square test for trend and no statistical significance with Fisher's exact test between each
511 trimester, ^x p = 0.0240 with Chi-square test for trend, ^y p = 0.0406 with Fisher exact test, ^z p = 0.0215, ^{aa} p =
512 0.0101 with Chi-square test for trend and no statistical significance between trimesters with Fisher's exact test,
513 ^{bb} p = 0.0101 with Chi-square test for trend with no statistical significance between trimesters with Fisher's exact
514 test (p=0.1023 between 1st versus 3rd trimesters), ^{cc} p < 0.0001 with Chi-square test for trend, ^{dd} p < 0.0001 with
515 Chi-square test for trend, ^{ee} Using two-way ANOVA testing and comparing the Amsterdam criteria to the severity
516 of COVID there was a P value of 0.0307 for COVID19 severity and 0.0136 for the Amsterdam criteria respectively
517 Using two-way ANOVA testing and comparing the Amsterdam criteria to the particular trimester, there was a P
518 value of 0.0231 for the trimester and 0.0249 for the Amsterdam criteria respectively, ^{gg} p = 0.0402 with Tukey's

multiple comparison with two-way ANOVA testing between mild versus severe COVID19, ^{hh} p = 0.0222 with Tukey's multiple comparison with two-way ANOVA testing between the first and third trimester results, ⁱⁱ p = <0.0001 with Chi-square test for trend, ^{jj} p = 0.0008 with Fisher's exact test, ^{kk} p <0.0001 with Fisher's exact test, ^{ll} p = 0.0001 with Fisher's exact test, ^{mm} p <0.0001 with Fisher's exact test, ⁿⁿ p=0.0440 with Fisher's exact test, ^{oo} p = 0.0006 with Chi-square test for trend, ^{pp} p=0.008 Fisher's exact test, ^{qq} p=0.0007 with Fisher's exact test, ^{rr} p=0.0291 with Chi-square test for trend, ^{ss} p=0.0300 with Fisher's exact test, ^{tt} p=0.0253 with Fisher's exact test, ^{uu} p=0.0274 with Chi-square test for trend, ^{vv} p=0.0095 with Fisher's exact test, ^{ww} p=0.0289 with Fisher's exact test, ^{xx} p<0.0001 with Chi-square test for trend, ^{yy} p<0.001 with Fisher's exact test, ^{zz} p<0.0001 with Fisher's exact test, ^{aaa} p=0.0014 with Fisher's exact test, ^{bbb} p = 0.0304 with Fisher's exact test, ^{ccc} p=0.0417 with Fisher's exact test, ^{ddd} p=0.0055 with Chi-square test for trend, ^{eee} p=0.0285 with Fisher's exact test, ^{fff} p=0.0417 with Fisher's exact test.

530 **Figure 1: Flow diagram of selection of study cohort.**

531

532 **Figure 2: Sex, weight, length, and head circumference distribution of infants within the study cohort.**

533

534 **Figure 3: RNAScope for SARS-CoV-2 and immunohistochemistry for SARS-CoV-2 spike protein**
 535 **demonstrate the absence of placental infection with SARS-CoV-2 in the single SARS-CoV-2 positive**
 536 **infant in our cohort.** (A-C) RNA-ISH of placenta for *SARS-CoV-2* RNA (A) and negative (bacterial *DapB*)
 537 (B) and positive (*UBC*) (C) controls. (D-E) IHC of placenta for SARS nucleocapsid (D) and isotype control
 538 (E). (F) IHC of COVID-19 trachea as a positive control. Bars: (A-E): 50 μ m. (F) 20 μ m.

539

540 **Figure 4: SARS-CoV-2-specific IgG antibodies in mothers and their infants.** Box and whisker plots
 541 demonstrating **A:** SARS-CoV-2 spike IgG antibody, **B:** SARS-CoV-2 spike glycoprotein S1 subunit IgG
 542 antibody, **C:** SARS-CoV-2 receptor-binding domain IgG antibody, **D:** SARS-CoV-2 spike glycoprotein 2
 543 subunit IgG antibody, and **E:** SARS-CoV-2 Nucleocapsid IgG antibody. **F:** SARS-CoV-2-surrogate
 544 neutralizing IgG antibody concentration and percent inhibition. The dashed red line is the threshold for
 545 a positive test with each respective antibody assay. ns = not significant. n=10.

546

547 **Figure 5: Amsterdam criteria, placental weight, placental weight to birth weight ratio, and placental**
 548 **weight percentiles of placentas within the study cohort.** **A:** Amsterdam criteria classification of the
 549 evaluated placentas. Maternal vascular malperfusion: n=26, 22.6%; Fetal vascular malperfusion: n=1,
 550 0.870%; Delayed villous maturation: n=1, 0.870%; Ascending intrauterine infection: n=28, 24.3%; Villitis
 551 of unknown etiology: n=4, 3.48%; Normal and/or non-specific findings: n=63, 54.8%. **B-C:** Scatter dot
 552 plot and bar graph of individual distribution of placental weights (**B**) and placental weight to birth
 553 weight ratio (**C**). Solid line of scatter dot plot represents median with error bars representing 95%
 554 confidence intervals. **D:** Placental weight percentiles[25] for all placentas, male, and female placentas.
 555 Solid black line represents the linear trend line. Dashed red represents the 2nd order polynomial trend
 556 line.

A.

B.

Newborn Weight Distribution

Frequency of Distribution of Newborn Weights

C.

Newborn Length Distribution

Frequency of Distribution of Newborn Lengths

D.

Newborn Head Circumference

Frequency of Distribution of Head Circumferences

A.

B.

Placental Weights Frequency Distribution of Placenta Weights

C.

Placental Weight to Fetal Weight Ratio Frequency Distribution of Placenta Weight to Birth Ratio

D.

All Placental Weight Percentiles

All Male Placental Weight Percentiles

All Female Placental Weight Percentiles